Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from Evaxion Biotech ( (EVAX) ) is now available.
On January 14, 2025, Evaxion Biotech announced the effective change in its American Depositary Share (ADS) to ordinary share ratio, shifting from one ADS representing ten ordinary shares to one ADS representing fifty ordinary shares. This adjustment, resembling a one-for-five reverse ADS split, aims to support liquidity in the company’s ADSs on Nasdaq. The change affects all shareholders uniformly and is expected to proportionally increase the ADS trading price, although no assurances are given regarding the exact impact on trading prices or liquidity.
More about Evaxion Biotech
Evaxion Biotech A/S is a pioneering TechBio company based in Denmark. It leverages its proprietary AI-Immunology platform to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. The company has a clinical-stage oncology pipeline and a preclinical infectious disease pipeline, focusing on high unmet medical needs.
YTD Price Performance: 0.59%
Average Trading Volume: 357,312
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.87M
See more data about EVAX stock on TipRanks’ Stock Analysis page.
